Jennitte Stevens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennitte Stevens has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Angela Coxon
Amgen Inc. 3 Thousand Oaks, CA
25 shared publications - Binnaz K. Staley
Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
25 shared publications - Bram Estes
Torrey Mesa Research Institute, Syngenta Research and Technology, 3115 Merryfield Row, San Diego, CA 92121, USA
25 shared publications - Christopher M. Murawsky
Therapeutic Discovery, Amgen Research, Amgen Inc., Burnaby, Canada
25 shared publications - Cong Li
Oncology Research, Amgen Research, Amgen Inc., South San Francisco, California
25 shared publications - Famke Aeffner
Amgen, Inc., South San Francisco, California, USA
25 shared publications
Latest Publications
- Open Access
SEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells
Chinese hamster ovary (CHO) cells are the dominant host for therapeutic protein production, yet intra- and inter-clonal heterogeneity in manufacturing phenotypes, and the underlying metabolic and secretory circuitry, remain poorly defined at single-cell resolution. Here, we apply secretion encoded single-cell sequencing (SEC-seq) to simultaneously measure transcriptomes and secreted IgG in single-cells from a parental production cell line and five CHO clones, each varying in cell-specific productivity. IgG mRNA and recombinant protein secretion are only moderately correlated across single cells, indicating that transcription alone does not explain intra-clonal secretion heterogeneity. By integrating SEC-seq with single-cell metabolic and secretory task scoring, we find that CHO cells accommodating recombinant protein expression burden have more active translation-associated pathways and suppressed energy-intensive endogenous secreted protein processing. Three high-secreting clones converge on this translation-focused state but differ in their subpopulation composition and energy/redox programs coupled to IgG output: one highly productive clone shows a low-growth, glycolytic, NAD/one-carbon–associated and UPR-activated program; a second shows increased oxidative phosphorylation and fatty-acid β-oxidation, and a third shows higher lipid-uptake with modest central carbon metabolism. Genes such as Aldoa, Ndufab1, Acsl5, Mthfd2 showed clone-specific correlations with IgG, linking glycolysis, mitochondrial respiration, fatty-acid metabolism, and redox to secretion. Together, these results demonstrate that SEC-seq can resolve IgG-coupled metabolic-secretory wiring within and between CHO clones, providing a framework to identify subpopulation and circuit features to engineer or select for improved recombinant protein production.
Open AccessSEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells
Chinese hamster ovary (CHO) cells are the dominant host for therapeutic protein production, yet intra- and inter-clonal heterogeneity in manufacturing phenotypes, and the underlying metabolic and secretory circuitry, remain poorly defined at single-cell resolution. Here, we apply secretion encoded single-cell sequencing (SEC-seq) to simultaneously measure transcriptomes and secreted IgG in single-cells from a parental production cell line and five CHO clones, each varying in cell-specific productivity. IgG mRNA and recombinant protein secretion are only moderately correlated across single cells, indicating that transcription alone does not explain intra-clonal secretion heterogeneity. By integrating SEC-seq with single-cell metabolic and secretory task scoring, we find that CHO cells accommodating recombinant protein expression burden have more active translation-associated pathways and suppressed energy-intensive endogenous secreted protein processing. Three high-secreting clones converge on this translation-focused state but differ in their subpopulation composition and energy/redox programs coupled to IgG output: one highly productive clone shows a low-growth, glycolytic, NAD/one-carbon–associated and UPR-activated program; a second shows increased oxidative phosphorylation and fatty-acid β-oxidation, and a third shows higher lipid-uptake with modest central carbon metabolism. Genes such as Aldoa, Ndufab1, Acsl5, Mthfd2 showed clone-specific correlations with IgG, linking glycolysis, mitochondrial respiration, fatty-acid metabolism, and redox to secretion. Together, these results demonstrate that SEC-seq can resolve IgG-coupled metabolic-secretory wiring within and between CHO clones, providing a framework to identify subpopulation and circuit features to engineer or select for improved recombinant protein production.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
AMG 509 cross-reactivity to other species.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
AMG 509 cross-reactivity to other species.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Cryo-EM data collection, refinement, and validation statistics.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Cryo-EM data collection, refinement, and validation statistics.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
This file contains Methods for Supplementary Data.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
This file contains Methods for Supplementary Data.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Antibodies used in this study.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Antibodies used in this study.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Antibodies used in this study.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Antibodies used in this study.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Avidity-dependent activity of AMG 509.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Avidity-dependent activity of AMG 509.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Summary of STEAP1 mRNA and Protein Expression in Normal Tissues.
- Open Access
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Binding properties of AMG 509 and monovalent anti-STEAP1 XmAb molecules.
- 12 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Binding properties of AMG 509 and monovalent anti-STEAP1 XmAb molecules.